Clinical Trials Directory

Trials / Unknown

UnknownNCT04892407

Algeness DF 3.5% Compared to Voluma in Volume Deficit in Mid-face

A Prospective, Multi-center, Randomized, Controlled, Single-blind Study of the Safety and Effectiveness of Algeness® DF 3.5% Deep Volumizing Filler to Correct Age-related Volume Deficit in the Mid-face

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
308 (estimated)
Sponsor
Advanced Aesthetic Technologies, Inc · Industry
Sex
All
Age
22 Years
Healthy volunteers
Accepted

Summary

A prospective, randomized, controlled study of Algeness® DF 3.5% Deep Volumizing Filler comparing to Juvéderm Voluma to correct midface volume loss.

Conditions

Interventions

TypeNameDescription
DEVICEAlgeness® DF 3.5%dermal filler CE Mark approved for treatment of cheek and midface volume loss
DEVICEJuvéderm Volumadermal filler CE Mark approved for treatment of cheek and midface volume loss

Timeline

Start date
2021-09-06
Primary completion
2022-12-01
Completion
2024-08-01
First posted
2021-05-19
Last updated
2022-06-27

Locations

9 sites across 7 countries: Belgium, France, Germany, Israel, Malaysia, Spain, United Arab Emirates

Source: ClinicalTrials.gov record NCT04892407. Inclusion in this directory is not an endorsement.

Algeness DF 3.5% Compared to Voluma in Volume Deficit in Mid-face (NCT04892407) · Clinical Trials Directory